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■ Abstract Longitudinal studies with very long follow-
up periods of patients with obsessive-compulsive disor-
der (OCD) who have received adequate treatment are
rare. In the current study, 30 of 37 inpatients (81 %) with
severe OCD were followed up 6–8 years after treatment
with cognitive-behavioral therapy (CBT) in combina-
tion with either fluvoxamine or placebo in a randomized
design. The significant improvements (with large effect-
sizes) in obsessive-compulsive symptoms from pre- to
post-treatment (41 % reduction on the Y-BOCS) re-
mained stable at follow-up (45 %). Responder rates, de-
fined as ≥35 % reduction on the Y-BOCS, were 67 % and
60 %, respectively. Depressive symptoms decreased sig-
nificantly not only from pre- to post-treatment but also
during follow-up. Re-hospitalization, which occurred in
11 patients (37 %), was associated with more severe de-
pressive symptoms at pre-treatment and living without
a partner. Full symptom remission at follow-up, defined
as both Y-BOCS total score ≤ 7 and no longer meeting
diagnostic criteria for OCD, was achieved by 8 patients
(27 %). Patients without full remission at follow-up had
a significantly longer history of OCD, assessed at pre-
treatment, compared to remitted patients. The short-
term treatment outcome had no predictive value for the
long-term course. Throughout the naturalistic follow-
up, nearly all patients (29 patients) received additional
psychotherapy and/or medication. This might indicate
that such chronic OCD patients usually need additional
therapeutic support after effective inpatient treatment
to maintain their improvements over long periods.
■ Key words obsessive-compulsive disorder · 
cognitive-behavioral therapy · fluvoxamine · outcome ·
follow-up
Introduction
Obsessive-compulsive disorder (OCD) is a severe and
disabling illness which is frequently associated with
considerable psychosocial handicaps and reduced qual-
ity of life comparable to those of psychotic disorders [4,
16, 17, 27]. The course of illness, if untreated, is mostly
chronic with varying intensity of symptoms [34,38].Un-
til 30 years ago, OCD was considered a treatment refrac-
tory illness. Since then, the development of cognitive-
behavior therapy (CBT) and, during the last years, of
non-selective and selective serotonin reuptake in-
hibitors (SRIs and SSRIs) has provided effective treat-
ments. Patients treated with medication alone showed
high relapse-rates following drug discontinuation [24,
33], whereas several prospective follow-up studies
showed that improvement after CBT tends to persist (for
a review, see [21, 25]). A meta-analysis of 6 studies with
follow-up periods of 7–24 months showed that treat-
ment gains were maintained up to 2 years after CBT [36].
However, longer follow-up periods are important in
chronic diseases to evaluate what happens after treat-
ment. Five- to 10-year follow-up studies are expected
after treatment of heart disease or cancer and are
equally valuable for serious mental health problems
[32]. Such follow-up studies of patients with chronic
OCD who have received effective treatments are rare.
In a 6-year follow-up study after exposure and
clomipramine therapy for 34 OCD inpatients, 25 pa-
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tients (74 %) were classified as “improved” or “much im-
proved”in a self-rating at follow-up (the Yale-Brown Ob-
sessive-Compulsive Scale was not used) [32]. However,
only 10 patients (29 %) remained drug-free throughout
the follow-up and 5 patients received further exposure
therapy.At the time of follow-up assessment,20 of 33 pa-
tients (61 %) were taking medication.
Although both CBT and pharmacological treatment
with (S)SRIs have proven to be effective in OCD, only a
few studies compared the combination of pharma-
cotherapy and CBT with CBT alone, with inconsistent
results (see the overview in [21]). Cottraux et al. [9]
found a short-term advantage for the combination of the
SSRI fluvoxamine with CBT compared to placebo plus
CBT. However, in the 48th week and at the 18-month fol-
low-up, no differences were detectable any more be-
tween the groups [8].Hohagen et al. [22] evaluated 49 in-
patients in a multicenter study, carried out in three
centers in Germany (Department of Psychiatry and Psy-
chotherapy, University of Freiburg; Department of Psy-
chiatry and Psychotherapy, University of Hamburg;
Central Institute of Mental Health at Mannheim). Pa-
tients were treated with CBT in combination with either
fluvoxamine or placebo in a double-blind, randomized
design. The following pre to post results were reported:
 Both treatment groups showed a highly significant
symptom reduction.
 There were no significant differences between the
groups concerning the total score of the Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS) and the sub-
score for compulsions.
 A significantly higher reduction of obsessions was
found in the combination treatment group than in
the CBT plus placebo group.
 Severely depressed patients receiving the combina-
tion treatment presented a significantly better treat-
ment outcome (Y-BOCS scores) than patients with
the CBT plus placebo treatment.
 The responder rate (defined as ≥35 % reduction on
the Y-BOCS) was significantly higher in the combi-
nation treatment group (n = 21; 88 %) than in the
CBT plus placebo group (n = 15; 60 %).
These results suggest that a combination of CBT and flu-
voxamine is superior to CBT alone, regarding the short-
term treatment results, when obsessions dominate the
clinical picture and/or when a severe secondary depres-
sion is present. However, so far, no follow-up study has
been published investigating the long-term course after
the end of the trial.
The present study reports the results of a 7-year fol-
low-up of inpatients who were treated in a double-blind,
randomized design in the University Hospital in Ham-
burg between 1993 and 1995. The two primary aims of
our study were [1] to evaluate the long-term develop-
ment of psychopathology, social functioning and the
frequency of additional treatments and re-hospitaliza-
tions during the naturalistic follow-up period and [2] to
examine the association of re-hospitalizations and full
symptom remission/non-remission at follow-up with
sociodemographic or clinical variables. A secondary
aim was to compare the short- and long-term outcome
of both treatment groups (CBT and fluvoxamine; CBT
and placebo).
Method
■ Patient sample
During 1993–1995,37 inpatients with chronic OCD were randomly al-
located to two experimental groups: In addition to CBT, one group re-
ceived fluvoxamine and the other group placebo. At study entry, all
patients received placebo during a 1-week period.After this wash-out
phase, they entered 9 weeks of treatment with CBT plus fluvoxamine
(250–300 mg) or CBT plus placebo. All patients were treated by expe-
rienced therapists with multimodal CBT including exposure in-vivo
and in-sensu as well as specific interventions for developmental
deficits (like social deficits) and problems in daily life conduct (for de-
tails of this concept, see Hand [20]). Exclusion criteria were: primary
affective disorder; current or previous psychotic disorder; current
substance abuse or dependency; organic brain disorder; epilepsy;
acute suicidal tendency; pregnancy. Twenty (54 %) of these patients
participated in the multicenter study mentioned above, for further
methodological details see [22].
Seven years (range: 6–8 years) after the end of the trail, all 37 pa-
tients were asked to participate in the follow-up. Those who refused
to come for a face to face interview were offered an interview by tele-
phone.Three patients (all from the group “CBT plus placebo”) refused
to participate. The main reasons were that they did not want to be re-
minded of their symptoms and their whole situation at the time of
hospitalization. Four patients (3 from the group “CBT plus placebo”,
1 from the group “CBT plus fluvoxamine”) could not be located. All
together, 30 out of 37 patients (81 %) were followed up, 21 by face to
face interview and 9 by telephone. Written consent was gained from
all participants and the trial was approved by the local ethical com-
mittee.
■ Assessments
Clinically experienced raters, who had not been involved in the pa-
tients’ treatments, conducted the expert ratings. The psychiatric diag-
nosis was determined at the start of trial using the Structured Clini-
cal Interview (SKID) for DSM-III-R [39] (German translation by
Wittchen et al. [44]). The severity of obsessive-compulsive symptoms
was rated at three assessment-points (pre-treatment, post-treatment,
follow-up) using the Y-BOCS [14, 15] (German translation by Bütt-
ner-Westphal and Hand [6]). The clinician-administered Y-BOCS is
regarded as the gold standard to assess the severity of obsessive-com-
pulsive symptoms. It comprises 10 items, rated on a 5-point Likert
scale ranging from 0 (no symptoms) to 4 (severe symptoms). The to-
tal score ranges from 0 to 40 and consists of two subscores for com-
pulsions (range 0 to 20) and obsessions (range 0 to 20). The severity
of depressive symptoms was assessed using the 21-item version of the
Hamilton Depression Rating Scale (HDRS) [18] (German translation
[7]), a clinician-administered instrument to quantify depressive
symptoms with a score range of 0 to 65. Apart from its utilization in
depression studies, the HDRS is often administered along with the Y-
BOCS in OCD research, as comorbid depressive symptoms are fre-
quent in OCD [30]. At follow-up, patients rated themselves by using
the Clinical Global Improvement (CGI) scale, comparing their com-
plaints at follow-up with pre-treatment.A score of 1 corresponds with
very much improved and 2 with much improved, 3 denotes minimal
improvement, and 4 represents no change. Scores of 5, 6, or 7 indicate
deterioration (minimally worse, much worse, or very much worse, re-
spectively).
In addition, all patients were submitted to a semistructured inter-
view regarding the course during the follow-up period, interim treat-
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ments and the status at follow-up. Psychiatric diagnoses at follow-up
were determined using the Mini International Neuropsychiatric In-
terview (MINI), a structured diagnostic psychiatric interview for
DSM-IV and ICD-10 [23, 37].
■ Statistical analysis
Chi-square tests or, when cell frequency was low, Fisher’s exact tests
were used for between-group comparisons for categorical variables,
Student’s t-test for continuous variables. Changes of continuous vari-
ables within a group were tested with the Wilcoxon paired t-test. The
scores of the Y-BOCS and HDRS, assessed at 3 time points (pre-treat-
ment; post-treatment; follow-up), were submitted to analyses of vari-
ance (ANOVAs) with repeated measures with time as within-subject
factor. In addition, the influence of the factor “treatment group” (CBT
and fluvoxamine versus CBT and placebo) was calculated. For 2 pa-
tients, the pre- and post-treatment results of the HDRS were not avail-
able; therefore, the analyses of the HDRS scores could only be calcu-
lated for 28 out of 30 patients.
In accordance with the multicenter study [22], a reduction of the
Y-BOCS total score by at least 35 % between pre- and post-treatment
was defined as short-term response. Correspondingly, long-term re-
sponse was defined as a reduction of the Y-BOCS score by at least 35 %
between pre-treatment and follow-up. The Statistical Package for So-
cial Sciences (SPSS), version 11.5, was used for all calculations.
Results
■ Follow-up participants versus non-participants
The 7 patients who were not rated at follow-up did not
differ from the 30 who were rated on any sociodemo-
graphic or psychometric measure at pre- or post-treat-
ment. The following mean Y-BOCS total scores were
found: 27.6 (SD = 4.3) in follow-up participants and 29.7
(SD = 4.1) in non-participants at pre-treatment (t = –1.2,
df = 35, P = 0.26); and at post-treatment 16.4 (SD = 7.4)
and 18.7 (SD = 6.1) respectively (t = –0.77, df = 35,
P = 0.45).
■ Pre-treatment data
The mean age of the follow-up participants, 12 men and
18 women, was 32.4 years (SD = 9.2). Thirteen patients
(43 %) were employed before treatment, more than a
third (38 %) of these were on sick leave before treatment.
Disabled or retired were 9 patients (30 %) and the other
8 patients (27 %) were students or doing housework.
Eighteen patients (60 %) were married or cohabiting.
The mean age at onset of OCD was 24.0 years
(SD = 9.3) with a mean duration of 8.3 years (SD = 7.3)
until the start of treatment. The mean Y-BOCS and
HDRS scores at pre-treatment are shown in Table 1.
Most patients (80 %) had severe or extreme obsessions
and compulsions (Y-BOCS total score above 23, see
Fig. 1), the mean Y-BOCS total score was 27.6 (SD = 4.3).
■ Symptom changes over the 10-weeks treatment
period and the follow-up period
Obsessive-compulsive symptoms
The follow-up assessment was carried out after a mean
period of 7.2 years (with a range of 6–8 years). At post-
treatment, the Y-BOCS total score was reduced by 41 %,
from 27.6 (SD = 4.3) at pre-treatment to 16.4 (SD = 7.4).
At follow-up, the mean Y-BOCS score was 14.9
(SD = 9.5), a reduction by 45 % compared to pre-treat-
ment. The repeated measures ANOVAs showed highly
significant time effects and large effect-sizes for the
changes of the Y-BOCS total scores and the two sub-
scores for obsessions and compulsions (Table 1). The
mean scores decreased highly significantly from pre- to
post-treatment, without significant changes from post-
treatment to follow-up.
Following several authors, e. g. Alonso et al. [1], the
ranges of the Y-BOCS total scores were divided into lev-
els of severity, in order to clarify the clinical significance
of a patient’s score. An individual scoring from 0 to 7 is
considered “subclinical” in relation to OCD symptoms, 8
to 15 “mild”, 16 to 23 “moderate”, 24 to 31 “severe”, and
a score of 32 or higher is considered “extreme”. The re-
sults are shown in Fig. 1.
From pre- to post-treatment, a significant shift to-
wards milder levels of symptom severity could be ob-
Fig. 1 Number of patients with respect to Y-BOCS
severity categories at pre-treatment, post-treatment
and after 7 years (n = 30)
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served. During follow-up, the number of patients with
mild symptoms declined from 10 to 5 patients, while the
number of patients with subclinical OCD symptoms
doubled from 4 to 8 patients. Almost unchanged re-
mained the number of patients with medium and severe
OCD symptoms (16 patients at post-treatment, 17 at fol-
low-up). Concerning the individual courses, 24 patients
(80 %) shifted to a lesser OCD severity level from pre- 
to post-treatment, 6 patients remained unchanged,
whereas none of the patients shifted to a higher severity
level. From post-treatment to follow-up, 12 patients re-
mained unchanged (40 %), 9 patients (30 %) shifted to a
lesser and also 9 patients to a higher OCD severity level.
None of the 8 patients with a subclinical degree of
OCD symptom severity met diagnostic criteria for OCD
according to the MINI at follow-up. From the other 22
patients with at least mild obsessive-compulsive symp-
toms at follow-up, 3 patients (13 %) showed an episodic
course during the follow-up period, characterized by
complete remission of OCD symptoms for a period of at
least 6 months, and 19 patients (87 %) showed a contin-
uous, chronic course.
Twenty patients (67 %) were classified as short-term
responders (≥ 35 % reduction on the Y-BOCS from pre-
to post-treatment) and 18 patients (60 %) as long-term
responders (≥ 35 % reduction on the Y-BOCS from pre-
treatment to follow-up). This difference was not signifi-
cant (McNemar Test: P = 0.75).
Depressive symptoms
The repeated measures ANOVA for the HDRS scores
showed a highly significant time effect (see Table 1). The
means of HDRS scores decreased significantly not only
from pre- to post-treatment but also from post-treat-
ment to follow-up.
Comparison of symptom-scores between both treatment
groups (CBT + fluvoxamine; CBT + placebo)
In addition to CBT, 19 patients received during the ran-
domized trial fluvoxamine and 11 patients placebo. At
pre-treatment, there were no significant differences in
sex,age,education,employment,marital status,duration
of OCD and severity of obsessive-compulsive and de-
pressive symptoms between the two treatment-groups
(data not shown).The repeated measures ANOVAs for the
Y-BOCS scores over the treatment and follow-up time
points did not show significant differences between the
groups: No significant group effects (all Fs (1,28) < 1.0,all
Ps > 0.28) and no significant interaction effects (all Fs
(2,56) < 1.6, all Ps > 0.22) were found for Y-BOCS total
scores and the two subscores (obsessions and compul-
sions).Similarly,ANOVA showed no significant group ef-
fects (F (1,26) = 1.24, P = 0.28) and interaction effects (F
(2,52) = 0.95, P = 0.39) for the HDRS scores. There were
also no significant differences between both treatment
groups concerning the frequencies responders/non-re-
sponders (at post-treatment χ2 = 0.07, df = 1, P = 0.79; at
follow-up χ2 = 1.53, df = 1, P = 0.22).
■ Re-hospitalization during the follow-up period:
frequency and association with psychopathological
and sociodemographic variables
During the follow-up period, 11 patients (37 %) were at
least once re-hospitalized. Psychopathological and so-
ciodemographic variables at the time of the randomized
trial were compared between re-hospitalized patients
and those without re-hospitalization (see Table 2). Sig-
nificant differences were only found for HDRS scores at
pre-treatment and the marital status. Patients who were
re-hospitalized during follow-up had at pre-treatment a
higher mean score of depression and were less often
married or cohabiting. In addition, a statistical trend
(t = –1.85, df = 28, P = 0.07) toward longer history of
OCD in re-hospitalized patients was seen.
■ Patients’ rating of improvement at follow-up
compared to pre-treatment
In the self-rated CGI,17 patients (57 %) rated themselves
as “much improved” or “very much improved” at follow-
up compared to pre-treatment (Fig. 2 shows the results
Table 1 ANOVAs with repeated measures (pre-treatment, post-treatment and follow-up) and paired t-tests for Y-BOCS and HDRS scores
Pre-treatment Post-treatment Follow-up ANOVA (df = 2)
F P Effect size partial Eta2
Y-BOCS: mean (SD) n = 30
Total 27.6 (4.3) 16.4 (7.4) 14.9 (9.5) F (58) = 39.24 < 0.0011 0.58
Compulsions 13.7 (1.9) 7.8 (3.7) 8.0 (4.7) F (58) = 35.11 < 0.0012 0.55
Obsessions 13.8 (2.9) 8.6 (4.3) 7.3 (4.9) F (58) = 32.76 < 0.0013 0.53
HDRS: mean (SD) n = 28 18.2 (8.6) 12.4 (9.9) 8.0 (7.9) F (54) = 16.05 < 0.0014 0.41
Y-BOCS Yale-Brown Obsessive Compulsive Scale; HDRS Hamilton Depression Rating Scale; ANOVA analysis of variance
1 Pre and post comparison: t = 9.2, df = 29, P < 0.001; post and follow-up comparison: t = 0.9, df = 29, P = 0.38 (paired t-tests)
2 Pre and post comparison: t = 8.2, df = 29, P < 0.001; post and follow-up comparison: t = –0.23, df = 29, P = 0.82 (paired t-tests)
3 Pre and post comparison: t = 8.0, df = 29, P < 0.001; post and follow-up comparison: t = 1.5, df = 29, P = 0.16 (paired t-tests)
4 Pre and post comparison: t = 3.0, df = 27, P < 0.01; post and follow-up comparison: t = 2.4, df = 27, P < 0.05 (paired t-tests)
121_128_Rufer_EAPCN_544  14.03.2005  11:01 Uhr  Seite 124
125
in more detail). The mean CGI score in all patients was
2.5 (SD = 1.6), in long-term responders 3.8 (SD = 1.6)
and in long-term non-responders 1.6 (SD = 0.6). This
difference between responders and non-responders was
highly significant (t = 5.1, df = 25, P < 0.001).
■ Changes in work status and marital status during 
the follow-up period
The number of patients who were married or cohabiting
slightly increased from 18 (60 %) at pre-treatment to 20
(67 %) at follow-up. The number of employed patients
also increased during this period, from 13 (43 %) to 17
(57 %). Two patients (7 %) were out of work at follow-up,
6 (20 %) were students or doing housework. Corre-
spondingly, the number of patients who were on sick
leave decreased from 5 (17 %) to 2 patients (7 %) and the
number of retired or disabled patients from 9 (30 %) to
7 (23 %).
■ Medication and/or psychotherapy during 
the follow-up period
Overall, 29 of the 30 patients were treated with psy-
chotherapy or medication for at least 3 months during
the follow-up period. Twenty-three patients (77 %) re-
ceived additional psychotherapy, 15 of these were
treated with CBT, 8 with other approaches of psy-
chotherapy (psychodynamic, client-centered and
other). Only 9 patients (30 %) remained without med-
ication during the entire follow-up period.At the follow-
up assessment, 13 patients (43 %) were taking medica-
tion: 10 were taking antidepressants (2 of these in
combination with benzodiazepines) and 3 were taking
benzodiazepines.The mean HDRS score in patients who
were taking medication at follow-up was 13.8 (SD = 8.7),
significantly higher compared to 5.0 (SD = 6.1) in pa-
tients without medication (t = –3.2, df = 28, P < 0.01). In
contrast, the mean Y-BOCS scores in both groups did
not differ significantly (t = –1.3, df = 28, P = 0.22).
■ Association of full symptom remission at follow-up
with psychopathological and sociodemographic
variables at the time of treatment
Remission at follow-up was defined as both no longer
meeting diagnostic criteria for OCD according to the
MINI and a Y-BOCS total score ≤ 7. The group of remit-
ters at follow-up was compared to the group of patients
with at least mild obsessive-compulsive symptoms at
follow-up with respect to psychopathological and so-
ciodemographic variables at the time of the randomized
trial (Table 3). Patients without a full symptom remis-
sion at follow-up had a highly significant longer history
of OCD, assessed at pre-treatment, compared to remit-
ted patients.
Table 2 Association of re-hospitalization with psychopathological and sociodemographic variables at the time of the randomized trial
Re-hospitalized patients Patients without re-hospitalization p value
(n = 11) (n = 19)
Male/female (n) 5/6 7/12 0.71a
Age (years): mean (SD) 30.7 (9.9) 33.3 (8.9) 0.47b
Years of school education: mean (SD) 11.7 (1.6) 10.9 (1.5) 0.17b
Married/not married or cohabiting (n) 4/7 14/5 df = 1, p = 0.04a
Employed/not employed patients (n) 4/7 9/10 0.71a
Duration of OCD (years): mean (SD) 11.5 (8.0) 6.5 (6.4) 0.07b
Fluvoxamine/placebo during randomized trial (n) 7/4 12/7 1.00a
Y-BOCS at the start of the randomized trial: mean (SD) 27.6 (5.1) 27.5 (3.9) 0.95b
Y-BOCS at the end of the randomized trial: mean (SD) 18.2 (8.1) 15.4 (7.0) 0.32b
HDRS at the start of the randomized trial: mean (SD) 23.8 (7.9) 15.6 (7.8) t = –2.6, df = 28, p = 0.02b
HDRS at the end of the randomized trail: mean (SD) 15.4 (9.5) 11.0 (10.0) 0.27b
Responderc/Non-responder at the end of the randomized trial (n) 6/5 14/5 0.43a
a Fisher’s exact test; b Student’s t-Test; c Responder: Y-BOCS reduction (pre-treatment to post-treatment) ≥ 35 %
Fig. 2 Patients’ rating of improvement at follow-up compared to pre-treatment
(n = 30)
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Discussion
Long-term course and outcome
In order to assess in detail the course of obsessive-com-
pulsive symptoms over the 7-year follow-up, we calcu-
lated (1) changes in the mean Y-BOCS scores, (2)
changes in the Y-BOCS severity categories and (3) short-
and long-term rates of response and remission. The fur-
ther slight (not significant) decrease of the mean Y-
BOCS scores from post-treatment to follow-up and the
higher rate of “remitters” (patients with subclinical ob-
sessive-compulsive symptoms and no longer meeting
diagnostic criteria for OCD according to the MINI) at
follow-up compared to post-treatment indicate a fur-
ther slight improvement during the follow-up period. In
contrast, the rate of non-responders slightly increased
(not significantly) during the follow-up period from 10
to 12 patients. However, the responder criterion of 35 %
or more reduction on the Y-BOCS is arbitrary and dis-
puted. Nevertheless, it has often been the criterion of
choice in previous treatment studies of OCD [e. g., 22,
29] and therefore, it is useful for comparing results of
different OCD studies. The responder rates of 67 % for
short-term outcome and 60 % for long-term outcome in
our study are in line with numerous previous studies
which demonstrated short- and long-term responder
rates of 50–80 % after CBT alone or in combination with
(S)SRIs [2, 5]. The clinical relevance of our long-term re-
sponder rate is supported by the results of the patients’
self-ratings: Similar to the responder-rate, 57 % of pa-
tients rated themselves as “much improved” or “very
much improved” at the 7-year follow-up compared to
pre-treatment and the long-term responders rated
themselves highly significantly better than the non-re-
sponders.
Similar to the results of the multicenter study by Ho-
hagen et al. [22], we found no significant differences be-
tween both treatment groups (CBT plus fluvoxamine;
CBT plus placebo) concerning obsessive-compulsive
symptoms (as measured by the Y-BOCS total score) and
compulsions. In contrast to the multicenter study, the
combination treatment in our study also did not show a
significantly better outcome for obsessions and depres-
sive symptoms and no higher responder rates. However,
the small sample size of our study clearly compromises
the statistical power to detect differences between these
two highly effective treatments for OCD and thus we can
not draw definite conclusions from this negative find-
ing.
In contrast to the stable obsessive-compulsive symp-
toms during follow-up, the severity of depressive symp-
toms significantly decreased not only from pre- to post-
treatment but also during follow-up. It must be noted
that primary depression was defined as an exclusion cri-
terion in our study. Thus, this further improvement af-
ter the end of treatment might be a delayed reaction to
the reduction of the distress caused by obsessive-com-
pulsive symptoms and its negative consequences for
work, social life and relationships. This assumption is
supported by our findings of positive changes in daily
functioning throughout the follow-up period. In addi-
tion, similar findings were reported in agoraphobics
with further amelioration of secondary depression dur-
ing long-term follow-up periods [19].However,when in-
terpreting our finding, one ought to keep in mind that
additional treatments during the naturalistic follow-up
period probably also have had a therapeutic effect on de-
pression.
Nearly all patients had received additional treat-
ments throughout the follow-up period. Regarding the
mostly chronic course of OCD in our patients (the mean
duration of OCD was 8 years at pre-treatment), the high
rate of additional treatments during the follow-up pe-
riod might indicate that such a group of patients with
chronic OCD usually need additional therapeutic sup-
port after an effective treatment to maintain their im-
provements over a very long time. Probably, these addi-
tional treatments have assumed a major role in the
Table 3 Association of long-term symptom remission with psychopathological and sociodemographic variables at the time of the randomized trial
Remission at follow-up At least mild OCD at follow-up p value
(n = 8) (n = 22)
Male/female (n) 2/6 10/12 0.42a
Age (years): mean (SD) 29.0 (6.2) 33.6 (9.9) 0.23b
Years of school education: mean (SD) 10.8 (1.4) 11.4 (1.6) 0.36b
Married/not married or cohabiting (n) 5/3 13/9 1.00a
Employed/not employed patients (n) 4/4 9/13 0.70a
Duration of OCD (years): mean (SD) 2.4 (1.4) 10.5 (7.4) t = –3.0, df = 28, p = 0.005b
Fluvoxamine/placebo during randomized trial (n) 6/2 13/9 0.67a
Y-BOCS at the start of the randomized trial: mean (SD) 27.8 (4.2) 27.5 (4.4) 0.89b
Y-BOCS at the end of the randomized trial: mean (SD) 14.4 (7.0) 17.1 (7.5) 0.38b
HDRS at the start of the randomized trial: mean (SD) 17.5 (6.0) 18.5 (9.6) 0.79b
HDRS at the end of the randomized trail: mean (SD) 10.1 (9.6) 13.3 (10.2) 0.46b
Responderc/Non-responder at the end of the randomized trial (n) 6/2 14/8 0.68a
a Fisher’s exact test; b Student’s t-Test; c Responder: Y-BOCS reduction (pre-treatment to post-treatment) ≥ 35 %
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long-term course. Because of our small sample size and
the lack of more detailed information on the extent and
duration of additional treatments, further analyses of
subgroups of our patients were limited. However, a com-
parison of the 13 patients who received drugs at the fol-
low-up assessment with the drug free patients might
help to explain the need of this medication treatment:
While the intensity of obsessive-compulsive symptoms
was not significantly different, the patients who received
medication were significantly more depressed. There-
fore, patients might have been drug-treated because of
depression rather than obsessive-compulsive symp-
toms. More prospective long-term follow-up studies
with larger sample-sizes are needed, specifically de-
signed to evaluate which factors are related to the need
of further drug treatments in patients with OCD after ef-
fective treatment.
■ Variables that were associated with 
re-hospitalization and long-term symptom
remission/non-remission
In view of the low quality of life in many patients with
OCD and the findings in various studies that 20 to 50 %
of patients do not achieve sufficient improvement with
CBT and/or (S)SRI [20, 21], predictors of outcome are
urgently needed. So far, in previous OCD studies most of
the examined variables have not been consistently asso-
ciated with outcome [29, 35, 42, 43]. The results of the
present study concerning the association of re-hospital-
ization with psychopathological and sociodemographic
variables showed that patients with more severe depres-
sive symptoms at pre-treatment were more often re-hos-
pitalized during the follow-up period. These findings
are in line with previous studies which reported a nega-
tive impact of comorbid depression on short- or long-
term outcome of CBT alone or in combination with
(S)SRI in obsessive-compulsives [11, 12, 26, 41]. How-
ever, in some other studies such an association was not
found [3, 13, 28, 32, 40]. These controversial results may
be partly due to the different treatment approaches used
in the different studies and the use of various psycho-
metric ratings, which clearly compromises the compa-
rability. The additional result of our study, that patients
who were married or cohabiting were less often re-hos-
pitalized, might be interpreted as an indication that liv-
ing together with a (marriage) partner can help some
patients to get over periods of increased symptoms
without the need of a re-hospitalization. However, we
have not enough data to confirm this interpretation and
more research is needed focusing on the possible impact
of close relationships on the risk of re-hospitalization
after inpatient CBT.
During the past decade many researchers empha-
sized that full remission should be the main treatment
goal for depression and anxiety disorders [10, 31]. In our
study, a highly significant association was found be-
tween the duration of illness before treatment and
achievement of symptom remission/non-remission at
follow-up: A longer history of OCD before treatment
was associated with non-remission at follow-up and
(but only as a statistical trend) with the need of re-hos-
pitalization during the follow-up period. These findings
are in accordance with the 2.5-year follow-up study by
Alonso et al. [1] in which 60 outpatients with OCD were
treated with CBT and (S)SRI: Long-term non-respon-
ders showed a statistical trend for a longer history of ill-
ness compared to responders. Conversely, in several
other CBT or drug studies the duration of OCD was not
associated with outcome of treatment [42, 43]. However,
follow-up periods of the most studies were only 1 to 3
years and the outcome of obsessive-compulsive symp-
toms was often measured by “response”rates (partial re-
mission) or by statistically significant improvement in
symptom rating scale scores. In conclusion, our study
points out that a very long duration of OCD before in-
patient treatment means a poorer likelihood to achieve
full remission of obsessive-compulsive symptoms sev-
eral years after treatment.
Finally, the two most important limitations of our
study need to be emphasized. First, the methodological
difficulties inherent in such naturalistic long-term fol-
low-up studies limit the possibilities to draw firm con-
clusions about specific treatment effects. Second, the
sample-size is rather small and 6 out of 17 patients of the
CBT plus placebo group did not take part in the follow-
up compared to only 1 out of 20 patients of the combi-
nation treatment group. However, the comparisons of
psychometric and sociodemographic variables between
follow-up participants and dropouts showed no signifi-
cant differences and the very high participation rate
(81 %) strengthens our results.
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